Product Description
JAB-30355 is an orally bioavailable small molecule activator for the treatment of patients with solid tumors harboring P53 Y220C mutation. (Sourced from: https://www.jacobiopharma.com/en/news/Jacobio_Pharma_Receives_IND_Approval_for_P53_Y220C_Activator_JAB-30355_in_the_US)
Mechanisms of Action: p53 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Jacobio
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for JAB-30355](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic: China, United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
JAB-30355-1001 | P2 |
Recruiting |
Oncology Solid Tumor Unspecified |
2027-01-01 |